RxDoctor Payments Data

Susan Martin, MD

Family Medicine · Rockport, INNPI 1184791618

Payments from drug & device makers

$5,952in general payments, 2019–2025

Across 439 payments — averaging $13.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Amgen$547
  • AstraZeneca$539
  • Novo Nordisk$315
  • Amarin Pharma, Inc.$283
  • Lilly USA, LLC$254
  • plus $3K from 34 others

What the payments were for

  • Food & beverage$5,74697%
  • Education$2073%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,952 in reported general payments places this provider in the 85th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$206,528
Medicare patients
262
Services billed
19,197

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol203$151,347
OzempicSemaglutide99$105,407
MounjaroTirzepatide58$67,450
EliquisApixaban83$63,173
VraylarCariprazine Hcl33$48,298
JardianceEmpagliflozin52$45,390
Trelegy ElliptaFluticasone/Umeclidin/Vilanter44$42,242
XareltoRivaroxaban38$37,850
RexultiBrexpiprazole17$37,759
MyrbetriqMirabegron34$27,105
GemtesaVibegron27$23,147
RybelsusSemaglutide24$22,343
EntrestoSacubitril/Valsartan26$22,009
JanuviaSitagliptin Phosphate23$21,821
Breztri AerosphereBudesonide/Glycopyr/Formoterol22$13,424

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$539$172,643243 claims
Novo NordiskOzempic, Rybelsus$315$127,751123 claims
Lilly USA, LLCMounjaro$254$67,45058 claims
AbbVieVraylar, Linzess, Synthroid$1,154$66,662134 claims
PfizerEliquis$244$63,17383 claims
GSKTrelegy Ellipta, Anoro Ellipta$149$47,84056 claims
Boehringer IngelheimJardiance$39$45,39052 claims
Johnson & JohnsonXarelto$93$37,85038 claims
Otsuka America Pharmaceutical, Inc.Rexulti$163$37,75917 claims
Astellas Pharma US IncMyrbetriq$55$27,10534 claims
Sumitomo Pharma America, Inc.Gemtesa$52$23,14727 claims
NovartisEntresto$241$22,00926 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Rockport

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →